We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


United and Debiopharm Announce the Launch of Pamorelin®

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) have announced the signature of an exclusive agreement for the distribution and commercialization of Pamorelin® 1, 3, and 6-month formulations in the Philippines, for the treatment of locally advanced and metastatic hormone-dependent prostate cancer and as adjuvant to radiotherapy in high-risk localized and locally advanced prostate cancer, and for the treatment of endometriosis (1- and 3-month formulations only).

Developed by Debiopharm, the product is manufactured in Switzerland by Debiopharm Research & Manufacturing SA and imported in the Philippines by Unilab. Pamorelin® LA will be made available primarily to urologists, oncologists and gynecologists across the Philippines.

“Our partnership with Debiopharm International SA adds more value to our mission as a pharmaceutical company that provides access to quality and affordable healthcare products and services,” says Jose Maria A. Ochave, Senior Vice President for Business Development Group of Unilab. “Our collaboration marks a significant step toward achieving a shared goal of providing options for better quality of life to more patients.”

“We are very happy to broaden the availability of our therapy for locally advanced and metastatic prostate cancer in Asia”, said Thierry Mauvernay, Co-President, Delegate of the Board of Debiopharm Group. “Prostate cancer is one of the most common cancers in men and we are keen on improving the quality of life of these patients. We are also pleased to offer a treatment option to women suffering from endometriosis.”